Chengbin Wu

Chengbin Wu is the CEO at EpimAb Biotherapeutics. Prior to this, they served as CSO and President of R&D at Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ). Chengbin has also held positions at Shanghai Ruizhi Huaxue Research Co., Ltd. and AbbVie.

Chengbin received their undergraduate degree in Biology from Fudan University in 2001. Chengbin went on to earn their PhD in Biological Sciences from Northwestern University in 2006.

During their time at CPGJ, Chengbin was responsible for the development of several groundbreaking biologics, including a dual variable domain immunoglobulin (DVD-Ig) that simultaneously targets multiple disease mediators. This work was published in Nature Biotechnology in 2007.

At AbbVie, Chengbin led the development of a new therapeutic antibody & biologics technology known as DVD-Ig. Chengbin has published extensively on this topic, with their work appearing in Drug News and Perspectives, mAbs, and Expert Opinion on Drug Discovery.

Chengbin Wu earned a B.E. in Biochemical Engineering from East China University of Science and Technology. Chengbin then went on to earn a Ph.D. in Biochemistry and Molecular Biology from The University of Georgia. Finally, they completed a postdoctoral fellowship in Molecular Immunology at Harvard Medical School.